deltatrials
Completed NCT00005520

Genetic Epidemiology of Responses to Antihypertensives

Sponsor: Mayo Clinic

Conditions Cardiovascular Diseases Heart Diseases Hypertension
Interventions Candesartan Hydrochlorothiazide
Updated 10 times since 2017 Last updated: Jan 15, 2013 Started: Feb 28, 1997 Primary completion: Jan 31, 2008 Completion: Jan 31, 2008

This observational or N/A phase trial investigates Cardiovascular Diseases and Heart Diseases and is currently completed. Mayo Clinic leads this study, which shows 10 recorded versions since 1997 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed

  2. Jul 2024 — Sep 2024 [monthly]

    Completed

  3. Dec 2021 — Jul 2024 [monthly]

    Completed

  4. Jan 2021 — Dec 2021 [monthly]

    Completed

  5. Nov 2020 — Jan 2021 [monthly]

    Completed

▶ Show 5 earlier versions

  1. Jun 2018 — Nov 2020 [monthly]

    Completed

  2. May 2018 — Jun 2018 [monthly]

    Completed

  3. Apr 2018 — May 2018 [monthly]

    Completed

    Phase: NA → None

  4. Aug 2017 — Apr 2018 [monthly]

    Completed NA

  5. Jan 2017 — Aug 2017 [monthly]

    Completed NA

    First recorded

Feb 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mayo Clinic
  • National Heart, Lung, and Blood Institute (NHLBI)
Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Rochester, United States